Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of GNC-401: temelimab in relapsing multiple sclerosis patients treated with rituximab
2021-001973-21Phase 2Terminated
- Sponsor
- GeNeuro
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temelimab in multiple sclerosis (MS), sponsored by GeNeuro. Primary endpoint: Incidence of adverse events and serious adverse events over 48 weeks. Started Jun 2021; status: terminated.
02
Drugs
temelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-001973-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001973-21.